OMass CEO Ros Deegan
Biotech

OMass’ $310M raise fuels goal to become ‘Britain’s Big Biotech’

OMass CEO Ros Deegan's ambition for the small-molecule biotech hasn't dimmed since Fierce last caught up with her two years ago.
James Waldron Oct 15, 2026 2:00am
iRegene Therapeuticss NouvSight001 Cleared for Clinical Trials in the US and China for Retinitis Pigmentosa

iRegene Therapeutics’s NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa

Brought to you by iRegene Therapeutics
cash money

OrbiMed’s largest-ever Asian fund contributes to $3B war chest

Oct 15, 2026 9:18am
AZ

AstraZeneca, insitro ink $1.5B AI-enabled target discovery deal

Oct 15, 2026 6:00am
A ballpoint pen rests on top of a stack of documents ready for signing

Rebranded Galapagos finally finds buyer for cell therapies

Oct 15, 2026 4:09am
IPO

Iambic goes public with $150M IPO to accelerate cancer pipeline

Oct 15, 2026 2:30am
More News

Vanda pauses social anxiety program after failing phase 3 trial

Oct 15, 2026 2:25am

IQVIA, Veeva expand partnership for speedier clinical trials

Oct 14, 2026 2:00pm

Merck KGaA spinout iOnctura touts PI3K inhibitor in eye cancer

Oct 14, 2026 1:42pm

Verastem CEO says RAS drug 'set new benchmark' for tricky cancer

Oct 14, 2026 10:27am